MONTREAL, QUEBEC--(Marketwire - November 07, 2007) - Thallion Pharmaceuticals Inc. (TSX: TLN) announced today that it will be presenting two sets of data from its ECO-4601 product candidate, an anti-cancer agent, during the month of November.
Thallion will present a comprehensive poster and abstract on the safety and efficacy data from the recently completed ECO-4601 Phase I/II trial on Thursday, November 15th at a joint meeting of the 4th International Society of Chemotherapy, Infection and Cancer International Conference on Cancer Therapeutics and the 7th Princess Margaret Hospital Conference: New Developments in Cancer Management in Toronto. The presentation will take place at the Metro Toronto Convention Center, Room 716, starting at 5:20 pm. Thallion's poster and abstract, reference number P-0035, are titled: Safety and efficacy of ECO-4601, a novel Ras/MAPK pathway inhibitor & PBR targeting agent, in a Phase I clinical trial.
